The management of graft-versus-host disease (GVHD) is a continuing problem in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Whereas considerable progress has been made in prevention and treatment of acute GVHD (aGVHD), chronic GVHD (cGVHD) remains virtually unsolved, diminishing the prognosis and quality of life of post-allo-HSCT patients. 1 There is no satisfactory animal model of cGVHD to study the immunological process of the disease. Accordingly, careful investigation of clinical samples obtained from cGVHD patients is of particular importance and it is the only reliable way to get insights into the pathogenesis of cGVHD.
OX40 (CD134), a member of tumor necrosis factor (TNF) receptor family, is expressed on activated CD4
þ as well as CD8
þ T cells. The interaction of OX40 with its ligand (OX40L), a TNF family molecule, generates costimulatory signals, resulting in enhanced T-cell proliferation and cytokine production. The OX40 ligation is known to be crucial for appropriate antigen presentation by dendritic cells leading to clonal expansion and long-term survival of antigen-specific T cells. 2 In murine models, several reports have indicated that the OX40/OX40L system plays an important role in the pathogenesis of aGVHD. 3 We have previously shown that the percentage of OX40 þ
CD4
þ T cells in peripheral blood correlated with the progression of cGVHD. 4 Then the obvious question appeared whether the interaction of OX40 and its ligand OX40L might be involved in the pathogenesis of cGVHD. To address the question, we examined the expression of OX40 and OX40L in the lesional skin specimens (Table 1) . Immunohistochemical studies 5 revealed that OX40 þ cells were present in the almost all skin specimens (10/11 in aGVHD and 11/13 in cGVHD) and OX40L
þ cells were present in the skin specimens in 6/11 aGVHD patients and, more notably, in 14/15 cGVHD patients (Figure 1a ) whereas such cells were absent or scarce in five normal controls (Figure 1j ). These OX40L þ cells were distributed in the dermis, especially around the blood vessels and the skin appendix ( Figure 1a) . OX40 þ cells, presumably T cells, were localized mainly in the epidermal and (Figure 1c-g ). CD20
þ cells were not detected in our samples (data not shown). Acidic toluidine blue staining revealed that the spindle-shaped cells containing metachromatically stained purple granules were distributed in the dermis especially around the blood vessels and the skin appendix. Interestingly, their distribution pattern and shape were quite similar to those of the OX40L þ cells (Figure 1h ). In addition, the double staining with human mast cell-specific anti-tryptase mAb (G3) and anti-OX40L mAb (8F4) showed that the majority of the OX40L þ cells in these samples were positive for tryptase (Figure 1k-p) . In aGVHD, expression of OX40L correlated inversely with the progression of grade (aGVHD grade 2-3 and 3 vs grade 1-2, Po0.05 tested by the w 2 test), whereas almost all samples expressed OX40L in cGVHD (extensive type vs limited type, P ¼ 0.24). Considering that the high-grade aGVHD involves fulminant inflammation in the skin, Next, we examined expression of OX40L on umbilical cord blood-derived mast cells in vitro. OX40L expression was induced on mast cells after the ligation of FceRI by immunoglobin E (IgE) and anti-IgE Ab but not by the treatment with IgE alone (Figure 1q ). OX40L on endothelial cells and dendritic cells has been reported to have a costimulatory function for T cells. 2 Then we analyzed whether mast cells interact with and costimulate T cells through the OX40/OX40L system. CD4
þ T cells were cocultured with anti-CD3-coated beads and preactivated cord blood-derived mast cells at the T cell/mast cell ratios of 10:1 and 50:1 in the presence of anti-OX40L mAb or control mouse IgG 1 . Preactivated mast cells induced proliferation of T cells, which was markedly inhibited by the addition of anti-OX40L mAb (Figure 1r ). These results showed that mast cells can express OX40L under certain conditions and induce T-cell proliferation through the OX40/OX40L system. Human tonsil-derived mast cells have been reported to augment T-cell proliferation through the OX40/OX40L system in vitro. 7 Our data not only confirmed the results using a different source of mast cells but also demonstrated expression of OX40L on skin mast cells in lesional skin samples of cGVHD, suggesting that its expression is dependent on the pathophysiological conditions in vivo. With regard to the cytokines that induce OX40L expression on mast cells, we previously reported that TNFa enhanced OX40L on the endothelial cells in vitro. 5 As cGVHD is not an allergic reaction but based on allogeneic responses, mast cells may be activated to express OX40L by some of proinflammatory cytokines such as TNFa rather than IgE in the skin of cGVHD.
Recently, the functions of mast cells are expanding from the specified effector cells in innate immunity and IgEdependent hypersensitivity to the cells participating in regulation of adaptive immune responses and tissue remodeling in normal and pathological conditions. 8 In addition, mast cells express both MHC class I and II molecules and may serve as one of the so-called nonprofessional antigen-presenting cells. 9 Accordingly, it is likely that T cell/mast cell interaction takes place in allogeneic immunological reactions. Indeed, in heart transplantation, the number of mast cells that infiltrate the graft has been shown to correlate with the manifestation of rejection. 10 These studies support our hypothesis that the lesional interaction between T cells and mast cells through the OX40/OX40L system plays a role in pathogenesis of cGVHD. Further studies are required to elucidate the biological consequences of the OX40/OX40L interaction between T cells and mast cells during the process of cGVHD.
